Proportion of males among drug-induced deaths in the European Union, Norway and Türkiye in 2024, or most recent year (percent)
Publication date
Description
This data visualisation was originally produced for the European Drug Report 2026: Trends and Developments.
Originally published in
Drug-induced deaths – the current situation in Europe (European Drug Report 2026)
Main subject
Target audience
Type
Copyright status
- Creative Commons Attribution 4.0 International (CC BY 4.0)
Related assets in the Media library
Previous slide
Next slide
| Term | Colour |
|---|---|
| increase | #ff7f00 |
| stable | #fec357 |
| decrease | #4b78bb |
| Term | Filter sort |
|---|---|
| Resin | 1 |
| Herbal | -1 |
| Term | Filter sort |
|---|---|
| Resin | -1 |
| Herbal | 1 |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Substance |
| 2 | Recall period |
| 3 | Age |
| 4 | Gender |
| 5 | Prevalence of drug use |
| 6 | Percent |
| 7 | Breakdown by substance |
| 8 | Prevalence all available countries |
| 9 | Trends |
| 11 | Males and females |
| 14 | Country |
| 15 |
Note: For methodological information and details on the data presented, please refer to the notes beneath the main map. |
| 16 | About the data |
| 17 | Currently not available for individual countries |
| 50 | Cannabis |
| 101 | prevalence of cannabis use |
| 102 | prevalence of cocaine use |
| 103 | prevalence of MDMA use |
| 104 | prevalence of amphetamine use |
| 105 | prevalence of methamphetamine use |
| 231 | Gender breakdown: all treatment entrants |
| 232 | Mean age: all treatment entrants |
| 233 | Client status – number of clients |
| 234 | First-time entrants |
| 235 | Previously treated entrants |
| 236 | Unknown status |
| 237 | Route of administration (%) |
| 238 | Injecting |
| 239 | Smoking/inhaling |
| 240 | Eating/drinking |
| 241 | Sniffing |
| 242 | Other |
| 243 | Frequency of use in the last month (%): all treatment entrants |
| 244 | 4 to 6 days per week |
| 245 | 2 to 3 days per week |
| 246 | Once a week or less |
| 247 | Not used in the last 30 days |
| 248 | Trends in first-time entrants |
| 250 | Cannabis market: data and trends |
| 252 | Years |
| 260 | Cannabis type |
| 261 | Daily |
| 265 | COVID-19 pandemic |
| 312 | Geographical coverage (selected graphs) |
| 315 | Number of seizures |
| 324 | Price retail (EUR/g) (EU) |
| 325 | Price wholesale (EUR/kg) (EU) |
| 330 | Quantity seized (tonnes) |
| 360 | Cannabis type |
| 370 | Potency retail (% THC) (EU) |
| 375 | Indexed trends, retail (2014=100) (EU) |
| 385 | Trends in number of seizures |
| 386 | Trends in quantity seized (tonnes) |
| 400 | mg/1000 population/day |
| 450 | Kilograms |
| 500 | Retail |
| 510 | Wholesale |
| 520 | Potency |
| 600 | cannabis |
| 610 | cocaine |
| 620 | amphetamine |
| 630 | methamphetamine |
| 640 | MDMA |
| 650 | ketamine |
| 100200 | Mean use: 4.2 days per week |
| 100201 | Mean use 3.3 days per week |
| Term | Filter sort |
|---|---|
| Lifetime | 100 |
| Last month | 1 |
| Last year | 20 |
| All adults (15-64) | 200 |
| Young adults (15-34) | 10 |
| Term | Filter sort |
|---|---|
| Cannabis | 1 |
| Cocaine | -1 |
| LSD | -1 |
| Ecstasy | -1 |
| Amphetamines | -1 |
| Tobacco | -1 |
| Alcohol | -1 |
| Category | Filter sort |
|---|---|
| EU | 1 |
| EU+2 | -1 |
| Austria | 101 |
| Belgium | 102 |
| Bulgaria | 103 |
| Croatia | 104 |
| Cyprus | 105 |
| Czechia | 106 |
| Denmark | 107 |
| Estonia | 108 |
| Finland | 109 |
| France | 110 |
| Germany | 111 |
| Greece | 112 |
| ID | Term |
|---|---|
| 10 | Tonnes |
| 50 | Amphetamine and methamphetamine |
| 55 | Heroin |
| 60 | Cathinones |
| 65 | Cocaine |
| 70 | MDMA |
| 80 | Kilograms |
| 90 | Litres |
| Substance | Color |
|---|---|
| Amphetamine | #FBAA19 |
| Cannabis | #B3D455 |
| Cannabis plants | #A6D6AA |
| Cannabis resin | #3d7000 |
| Cocaine and crack | #87D3E1 |
| Cocaine | #87D3E1 |
| Herbal cannabis | #B3D455 |
| Heroin | #7DA7D8 |
| MDMA | #F58465 |
| Methamphetamine | #D17219 |
| Amphetamines | #FEC357 |
| Other substances | #ABADB0 |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Substance |
| 2 | Recall period |
| 3 | Age |
| 4 | Gender |
| 5 | Prevalence of drug use |
| 6 | Percent |
| 7 | Breakdown by substance |
| 8 | Prevalence all available countries |
| 9 | Trends |
| 11 | Males and females |
| 14 | Country |
| 15 | Years |
| 16 | About the data |
| 17 | Currently not available for individual countries |
| 20 |
Note: For methodological information and details on the data presented, please refer to the notes beneath the main map. |
| 101 | prevalence of cannabis use |
| 102 | prevalence of cocaine use |
| 103 | prevalence of MDMA use |
| 104 | prevalence of amphetamine use |
| 105 | prevalence of methamphetamine use |
| 231 | Gender breakdown: all treatment entrants |
| 232 | Mean age: all treatment entrants |
| 233 | Client status — number of clients |
| 234 | First-time entrants |
| 235 | Previously treated entrants |
| 236 | Unknown status |
| 237 | Route of administration (%): all treatment entrants |
| 238 | Injecting |
| 239 | Smoking/inhaling |
| 240 | Eating/drinking |
| 241 | Sniffing |
| 242 | Other |
| 243 | Frequency of use in the last month (%): all treatment entrants |
| 244 | 4 to 6 days per week |
| 245 | 2 to 3 days per week |
| 246 | Once a week or less |
| 247 | Not used in the last 30 days |
| 248 | Trends in first-time treatment entrants |
| 250 | Cannabis market: data and trends |
| 260 | Cannabis type |
| 261 | Daily |
| 265 | COVID-19 pandemic |
| 312 | Geographical coverage (selected graphs) |
| 315 | Number of seizures |
| 324 | Price retail (EUR/g) (EU) |
| 325 | Price wholesale (EUR/kg) (EU) |
| 330 | Quantity seized (tonnes) |
| 360 | Cannabis type |
| 370 | Potency (%) |
| 372 | Purity (%) (EU) |
| 375 | Indexed trends: retail (2014 = 100) (EU) |
| 385 | Trends in number of seizures |
| 386 | Trends in quantity seized (tonnes) |
| 390 | Retail |
| 391 | Wholesale |
| 395 | Purity |
| 396 | Potency |
| 400 | mg/1000 population/day |
| 500 | cannabis |
| 510 | cocaine |
| 520 | amphetamine |
| 530 | methamphetamine |
| 540 | MDMA |
| 550 | ketamine |
| 600 | Cocaine |
| 605 | Crack cocaine |
| 610 | Powder cocaine |
| 700 | Year |
| 100200 | Mean use: 4.3 days per week |
| 100201 | Mean use 4.3 days per week |
| 100210 | Mean use 4.3 days per week |
| 100220 | Mean use 3.2 days per week |
| Term | Filter sort |
|---|---|
| Lifetime | 100 |
| Last month | 1 |
| Last year | 20 |
| All adults (15-64) | 200 |
| Young adults (15-34) | 10 |
| Term | Filter sort |
|---|---|
| Cannabis | -1 |
| Cocaine | 1 |
| LSD | -1 |
| Ecstasy | -1 |
| Amphetamines | -1 |
| Tobacco | -1 |
| Alcohol | -1 |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Substance |
| 2 | Recall period |
| 3 | Age |
| 4 | Gender |
| 5 | Prevalence of drug use |
| 6 | Percent |
| 7 | Breakdown by substance |
| 8 | Prevalence all available countries |
| 9 | Trends |
| 11 | Males and females |
| 14 | Country |
| 15 |
Note: For methodological information and details on the data presented, please refer to the notes beneath the main map. |
| 16 | About the data |
| 17 | Currently not available for individual countries |
| 101 | prevalence of cannabis use |
| 102 | prevalence of cocaine use |
| 103 | prevalence of MDMA use |
| 104 | prevalence of amphetamine use |
| 105 | prevalence of methamphetamine use |
| 231 | Gender breakdown |
| 232 | Age profile |
| 233 | Client status |
| 234 | First-time entrants |
| 235 | Previously treated entrants |
| 236 | Unknown status |
| 237 | Route of administration (%) |
| 238 | Injecting |
| 239 | Smoking/inhaling |
| 240 | Eating/drinking |
| 241 | Sniffing |
| 242 | Other |
| 243 | Frequency of use in the last month (%) |
| 244 | 4 to 6 days per week |
| 245 | 2 to 3 days per week |
| 246 | Once a week or less |
| 247 | Not used in the last 30 days |
| 248 | Trends in new treatment entrants |
| 250 | Cannabis market: data and trends |
| 260 | Cannabis type |
| 261 | Daily |
| 265 | COVID-19 pandemic |
| 312 | Geographical coverage (selected graphs) |
| 315 | Number of seizures |
| 324 | Price retail (EUR/g) (EU) |
| 325 | Price wholesale (EUR/kg) (EU) |
| 330 | Quantity seized (tonnes) |
| 332 | Quantity seized |
| 335 | Quantity seized (tablets) |
| 337 | Quantity seized (million tablets) |
| 360 | Cannabis type |
| 365 | Form |
| 370 | Potency (%) |
| 375 | Indexed trends: retail (2014=100) (EU) |
| 377 | Indexed trends: price and MDMA content, retail (2014=100) |
| 385 | Trends in number of seizures |
| 386 | Trends in quantity seized (kg) |
| 387 | Trends in the number of MDMA seizures (all forms) |
| 388 | Trends in the quantity of MDMA seized Tablets |
| 390 | Trends in the quantity of MDMA seized Powder/crystal (tonnes) |
| 400 | mg/1000 population/day |
| 450 | Price retail (EUR/tablet) (EU) |
| 453 | Price retail (EUR/g powder) (EU) |
| 455 | Price wholesale (EUR/1000 tablets) (EU) |
| 460 | MDMA content retail (mg/tablet) (EU) |
| 465 | Purity powder retail (% MDMA) (EU) |
| 600 | cannabis |
| 610 | cocaine |
| 620 | amphetamine |
| 630 | methamphetamine |
| 640 | MDMA |
| 650 | ketamine |
| 660 | Percent of samples |
| 665 | Purity |
| 670 | MDMA per tablet |
| 100200 | Mean use: 4.3 days per week |
| 100201 | Mean use 3.3 days per week |
| Term | Filter sort |
|---|---|
| Lifetime | 100 |
| Last month | 1 |
| Last year | 20 |
| All adults (15-64) | 200 |
| Young adults (15-34) | 10 |
| MDMA powder | 1 |
| MDMA tablets | -1 |
| Term | Filter sort |
|---|---|
| MDMA Powder | -1 |
| MDMA Tablets | 1 |
| Term | Filter sort |
|---|---|
| Cannabis | -1 |
| Cocaine | -1 |
| LSD | -1 |
| Ecstasy | 1 |
| MDMA | 1 |
| Amphetamines | -1 |
| Tobacco | -1 |
| Alcohol | -1 |
| Tablet | 1 |
| Powder | 2 |
| Term | Filter sort |
|---|---|
| Tablet | 1 |
| Powder | 10 |
| Any | -1 |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Substance |
| 2 | Recall period |
| 3 | Age |
| 4 | Gender |
| 5 | prevalence of drug use |
| 6 | Percent |
| 7 | Breakdown by substance |
| 8 | prevalence all available countries |
| 9 | Trends |
| 11 | Males and females |
| 14 | Country |
| 15 |
Note: For methodological information and details on the data presented, please refer to the notes beneath the main map. |
| 16 | About the data |
| 50 | Years |
| 17 | Currently not available for individual countries |
| 101 | prevalence of cannabis use |
| 102 | prevalence of cocaine use |
| 103 | prevalence of MDMA use |
| 104 | prevalence of amphetamines use |
| 105 | prevalence of methamphetamine use |
| 231 | Gender breakdown: all treatment entrants |
| 232 | Mean age: all treatment entrants |
| 233 | Client status – number of clients |
| 234 | First-time entrants |
| 235 | Previously treated entrants |
| 236 | Unknown status |
| 237 | Route of administration: all treatment entrants (%) |
| 238 | Injecting |
| 239 | Smoking/inhaling |
| 240 | Eating/drinking |
| 241 | Sniffing |
| 242 | Other |
| 243 | Frequency of use in the last month (%): all treatment entrants |
| 244 | 4 to 6 days per week |
| 245 | 2 to 3 days per week |
| 246 | Once a week or less |
| 247 | Not used in the last 30 days |
| 248 | Trends in new treatment entrants |
| 249 | Trends in all treatment entrants |
| 250 | Cannabis market: data and trends |
| 260 | Cannabis type |
| 261 | Daily |
| 265 | COVID-19 pandemic |
| 312 | Geographical coverage (selected graphs) |
| 315 | Number of seizures |
| 324 | Price retail (EUR/g) (EU) |
| 325 | Price wholesale (EUR/kg) (EU) |
| 330 | Quantity seized (tonnes) |
| 332 | Quantity seized |
| 335 | Quantity seized (tablets) |
| 337 | Quantity seized (million tablets) |
| 360 | Cannabis type |
| 365 | Substance |
| 370 | Potency (%) |
| 372 | Purity (%) |
| 374 | Purity retail (%) (EU) |
| 375 | Indexed trends, retail (2014=100) (EU) |
| 377 | Indexed trends: price and purity, retail (2014=100) (EU) |
| 380 | Indexed trends: purity, retail (2014=100) (EU) |
| 385 | Trends in number of seizures |
| 386 | Trends in quantity seized (kg) |
| 387 | Trends in the number of MDMA seizures (all forms) |
| 388 | Trends in the quantity of MDMA seized Tablets (millions) |
| 390 | Trends in the quantity of MDMA seized Kilograms (powder/crystal) |
| 395 | Trends in quantity seized (tonnes) |
| 397 | Tonnes |
| 400 | mg/1000 population/day |
| 450 | Price retail (EUR/tablet) |
| 453 | Price retail (EUR/g powder) |
| 455 | Price wholesale (EUR/1000 tablets) |
| 460 | Content retail (mg/tablet) |
| 465 | Purity powder retail (%) |
| 470 | Entrants for this substance as a share of all first-time treatment entrants |
| 490 | Retail |
| 491 | Wholesale |
| 495 | Purity |
| 496 | Potency |
| 500 | cannabis |
| 510 | cocaine |
| 520 | amphetamine |
| 530 | methamphetamine |
| 540 | MDMA |
| 550 | ketamine |
| 100200 | Mean use: 3.1 days per week |
| 100201 | Mean use 3.8 days per week |
| 100210 | Mean use 3.2 days per week |
| Term | Filter sort |
|---|---|
| Lifetime | 100 |
| Last month | 1 |
| Last year | 20 |
| All adults (15-64) | 200 |
| Young adults (15-34) | 10 |
| Term | Filter sort |
|---|---|
| Cannabis | -1 |
| Cocaine | -1 |
| LSD | -1 |
| Ecstasy | -1 |
| MDMA | -1 |
| Amphetamines | 1 |
| Tobacco | -1 |
| Alcohol | -1 |
| Tablet | 1 |
| Powder | 2 |
| Term | Filter sort |
|---|---|
| methamphetamine | 1 |
| amphetamine | -1 |
| Term | Filter sort |
|---|---|
| Methamphetamine | 1 |
| Amphetamine | -1 |
| Term | Filter sort |
|---|---|
| Cannabis | -1 |
| Cocaine | -1 |
| Amphetamine | 1 |
| Methamphetamine | 10 |
| Cathinones | -1 |
| Term | Filter sort |
|---|---|
| Cannabis | -1 |
| Cocaine | -1 |
| Amphetamine | -1 |
| Methamphetamine | -1 |
| Cathinones | 1 |
| Term | Filter sort |
|---|---|
| EU | 1 |
| EU+2 | 2 |
| Amphetamine | 1 |
| Methamphetamine | -1 |
| Term | Filter sort |
|---|---|
| EU | 1 |
| EU+2 | 2 |
| Amphetamine | -1 |
| Methamphetamine | 1 |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Substance |
| 2 | Prevalence type |
| 3 | Age |
| 4 | Gender |
| 5 | prevalence of drug use |
| 6 | percentage (%) |
| 7 | Breakdown by substance |
| 8 | prevalance all available countries |
| 9 | Trends |
| 11 | Males and females |
| 14 | Country |
| 16 | About these data |
| 17 | Currently not available for individual countries |
| 20 | Years |
| 101 | prevalence of cannabis use |
| 102 | prevalence of cocaine use |
| 103 | prevalence of MDMA use |
| 104 | prevalence of amphetamine use |
| 105 | prevalence of methamphetamine use |
| 110 | Percent |
| 231 | Gender breakdown: all treatment entrants |
| 232 | Mean age: all treatment entrants |
| 233 | Client status – number of clients |
| 234 | First-time entrants |
| 235 | Previously treated entrants |
| 236 | Unknown status |
| 237 | Route of administration (%): all treatment entrants |
| 238 | Injecting |
| 239 | Smoking/inhaling |
| 240 | Eating/drinking |
| 241 | Sniffing |
| 242 | Other |
| 243 | Frequency of use in the last month (%): all treatment entrants |
| 244 | 4 to 6 days per week |
| 245 | 2 to 3 days per week |
| 246 | Once a week or less |
| 247 | Not used in the last 30 days |
| 248 | Trends in first-time treatment entrants |
| 250 | Cannabis market: data and trends |
| 260 | Cannabis type |
| 261 | Daily |
| 265 | COVID-19 pandemic |
| 312 | Geographical coverage (selected graphs) |
| 315 | Number of seizures |
| 324 | Heroin base, retail price (EUR/g) (EU) |
| 325 | Price wholesale (EUR/kg) (EU) |
| 326 | Heroin hydrochloride, retail price (EUR/g) (EU) |
| 328 | Heroin base, wholesale price (EUR/g) (EU) |
| 329 | Heroin hydrochloride, wholesale price (EUR/g) (EU) |
| 330 | Quantity seized (tonnes) |
| 340 | Heroin base, purity (%) (EU) |
| 345 | Heroin hydrochloride, purity (%) (EU) |
| 350 | Retail |
| 353 | Wholesale |
| 355 | Purity |
| 360 | base |
| 365 | hydrochloride |
| 370 | Potency (%) |
| 372 | Purity (%) (EU) |
| 375 | Indexed trends: retail (2014=100) (EU) |
| 385 | Trends in number of seizures |
| 386 | Trends in quantity seized (tonnes) |
| 400 | mg/1000 population/day |
| 500 | Treatment status |
| 550 | Share of presentations with heroin involved (%) |
| 100200 | Mean use: 4.7 days per week |
| Term | Filter sort |
|---|---|
| First-time | -1 |
| Previously treated | 1 |
| Term | Filter sort |
|---|---|
| First-time | 1 |
| Previously treated | -1 |
| Term | Filter sort |
|---|---|
| Cannabis | -1 |
| Cocaine | -1 |
| Heroin | 1 |
| Amphetamine | -1 |
| Methamphetamine | -1 |
| Cathinones | -1 |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Number of people who inject drugs |
| 2 | Prevalence of people who inject drugs (per 1 000 population) |
| 3 | Percent |
| 5 | Number of people |
| 8 | Per 1000 population |
| 50 | Percentage positive (%) |
| 100 | Location of cities participating in ESCAPE syringe analysis project |
| 200 | Amsterdam |
| 210 | Barcelona |
| 220 | Athens |
| 230 | Budapest |
| 240 | Cologne |
| 250 | Dublin |
| 260 | Helsinki |
| 270 | Heraklion |
| 275 | Brno |
| 280 | Klaipeda |
| 290 | Madrid |
| 300 | Oslo |
| 310 | Paris |
| 320 | Patras |
| 330 | Prague |
| 340 | Riga |
| 350 | Split |
| 360 | Tallinn |
| 370 | Thessaloniki |
| 380 | Vilnius |
| 390 | Cologne |
| 400 | Volos |
| 410 | Cork |
| 420 | Limerick |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Number |
| 2 | Kilograms |
| 3 | Age |
| Substance | Color |
|---|---|
| Amphetamine | #FBAA19 |
| Cannabis | #B3D455 |
| Cannabis plants | #A6D6AA |
| Cannabis resin | #3d7000 |
| Cocaine and crack | #87D3E1 |
| Cocaine | #87D3E1 |
| Herbal cannabis | #B3D455 |
| Heroin | #7DA7D8 |
| MDMA | #F58465 |
| Methamphetamine | #D17219 |
| Amphetamines | #FEC357 |
| Other substances | #ABADB0 |
| Aminoindanes | #83358C |
| Arylalkylamines | #D7CCE1 |
| Arylcyclohexylamines | #FBD1C2 |
| Benzodiazepines | #9687AB |
| Cannabinoids | #BED242 |
| Cathinones | #F08262 |
| Opioids | #EC5A7A |
| Others | #B2B2B2 |
| Unspecified NPS | #B2B2B2 |
| Phenethylamines | #8CADDC |
| Piperazines | #9F761C |
| Piperidines and pyrrolidines | #A8D4AF |
| Indolalkylamines (tryptamines) | #EC97AD |
| Plants and extracts | #486929 |
| Ketamine | #f4b5a6 |
| GHB/GBL | #73BCC7 |
| ID | Term |
|---|---|
| 0 | Close |
| 1 | Number of seizures |
| 2 | Quantity seized (kg) |
| 3 | Age |
| 5 | Number of notifications |
| 10 | mg/1000 population/day |
| 100 | ketamine |
| 200 | Percentage of presentations |
| ID | Term |
|---|---|
| 5 | Prevalence (percent) |
| 10 | Notifications per million population |
| 20 | COVID-19 pandemic |
| 30 | UNAIDS target (a 75 % reduction compared with 2010) |
| 40 | Year (only applicable while viewing map) |
| 50 | Associated drug |
| 55 | Cases |
| 60 | Location |
| 70 | Most recent HIV outbreaks (all available years) |
| 80 | WHO 2025 target |
| 90 | WHO target |
| 100 | Number of syringes per person who injects drugs per year |
| 110 | Cologne |
| 111 | Dublin |
| 112 | Helsinki |
| 113 | Lithuania (prison) |
| 114 | Luxembourg |
| 115 | Bavaria |
| 120 | Monza |
| 125 | Thessaloniki |
| 200 | Location of most-recent HIV outbreaks and associated substance |
| 500 | Number of syringes per person who injects drugs per year |
| 1000 | New HIV cases attributable to injecting drug use: 980 |
| 1005 | As a share of all new HIV cases (percent) |
| 1010 | New AIDS cases attributable to injecting drug use: 186 |
| 1015 | As a share of all new AIDS cases (percent) |
| 1020 | Trends in drug-related HIV: EU and selected countries Cases per million population |
| 1050 | Countries with national data |
| 2000 | HCV antibody prevalence among people who inject drugs 2023/2024 |
| 2005 | 19 % to 72 % |
| 2010 | in 9 countries |
| 2020 | Countries with national data |
| 2025 | HCV active infections among people who inject drugs 2023/2024 |
| 2030 | 7 % to 56 % |
| 2035 | in subnational samples in 6 countries |
| 2040 | HBV active infections, national data for 2023/2024 |
| 2045 | an average of 3.1 % (0.0-5.8 %) |
| 2050 | among people who inject drugs |
| 2100 | HIV and AIDS |
| 2200 | HCV and HBV |
| 2300 | Average of available studies |
| 2500 | ECDC (data) | HighCharts (Chart tool) |
| ID | Term |
|---|---|
| 10 | Breakdown by sex (percent) |
| 20 | Mean age at death (years) |
| 30 | Males |
| 40 | Females |
| 50 | Deaths with opioids present (percent) |
| 60 | Number of deaths |
| 70 | Males |
| 80 | Share with opioids (percent) |
| 90 | Share with opioids (percent) |
| 100 | Percentage with opioids (percent) |
| 110 | or most recent year |
| 120 | Percent |
| 130 | Rate per million population |
| 150 | Total number of drug-induced deaths with available toxicology, by country |
| 160 | Proportion (percent) of drug-induced deaths cases with at least one opioid mentioned (top) and proportion of specific opioids reported by country (bottom) |
| 165 | Proportion (%) of cases with specific opioids |
| 180 | Age at death |
| 1000 | Austria |
| 1100 | Slovenia |
| 1200 | Norway |
| ID | Term |
|---|---|
| 10 | WHO target |
| 20 | Recent/penultimate |
| 30 | Number in treatment |
| 40 | Gender breakdown (percent) |
| 50 | Trends in the number in opioid agonist treatment |
| 60 | Age distribution |
| 70 | Type of medication |
| 80 | Treatment duration (months) |
| 90 | Number of countries |
| 100 | 2024 or most recent |
| 110 | Previous estimate |
| 120 | Percent |
| ID | Term |
|---|---|
| 10 | WHO 2025 target |
| 20 | Proportion of people who use opioids receiving opioid agonist treatment |
| 30 | WHO 2025 target |
| 40 | Number of sterile syringes per person who injects drugs per year |
| 45 | Number people who inject drugs |
| 50 | Click to zoom in. Number of sites: |
| 55 | Number of countries |
| 60 | sites |
| 70 | Availability of interventions in prison settings |
| 80 | Select an intervention from the dropdown list below |
| 90 | Number of facilities at location |
| Term | Colour |
|---|---|
| Available | #92c020 |
| Not available | #d9562a |
| Unavailable | #d9562a |
| Unknown | #a3a3a3 |
| Status unknown | #a3a3a3 |
| Reference | Term |
|---|---|
| 10 | At |
| 20 | Not used in the last year (%) |
| 25 | Never used (%) |
| 30 | Other |
| 50 | Last year use |
| 55 | Lifetime use |
| 57 | National estimates of use in last year (%) |
| 60 | Cannabis |
| 61 | Cocaine |
| 62 | MDMA |
| 63 | Amphetamines |
| 64 | Heroin and other opioids |
| 65 | Adults (15-64) |
| 67 | Young adults (15-34) |
| 70 | million |
| 80 | Lowest |
| 90 | Highest |
| 200 | High-risk opioid users |
| 210 | Drug treatment requests |
| 220 | Fatal overdoses |
| c15-64-lyu | 24.9 |
| c15-64-lyu% | 8.7 |
| c15-64-ltu | 89.5 |
| c15-64-ltu% | 31.3 |
| c15-34-lyu | 15.4 |
| c15-34-lyu% | 15.3 |
| co15-64-lyu | 4.3 |
| co15-64-lyu% | 1.5 |
| co15-64-ltu | 18 |
| co15-64-ltu% | 6.3 |
| co15-34-lyu | 2.5 |
| co15-34-lyu% | 2.5 |
| m15-64-lyu | 3.1 |
| m15-64-lyu% | 1.1 |
| m15-64-ltu | 14.3 |
| m15-64-ltu% | 5 |
| m15-34-lyu | 2.4 |
| m15-34-lyu% | 2.4 |
| a15-64-lyu | 2 |
| a15-64-lyu% | 0.7 |
| a15-64-ltu | 11.7 |
| a15-64-ltu% | 4.1 |
| a15-34-lyu | 1.4 |
| a15-34-lyu% | 1.4 |
| a15-34-lyu% | 1.4 |
| 300 | 855 000 |
| 310 | 505 000 |
| 350 | opioid users received agonist treatment in 2024 |
| 360 | Principal drug in about 21 % of all drug treatment requests in the European Union |
| 361 | 21 % |
| 370 | Opioids were found in 66 % of fatal overdoses |
| 371 | 66 % |